Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Istradefylline: A novel agent in the treatment of “off” episodes associated with levodopa/carbidopa use in Parkinson disease
L. Cummins, Marshall E. Cates
Mental Health Clinician (2022) Vol. 12, Iss. 1, pp. 32-36
Open Access | Times Cited: 20

Showing 20 citing articles:

A novel electrochemical sensor based on collaborative performance enhancement of hybrid Acid Orange 10 polymer/zirconium nanoparticles for first voltammetric determination of Istradefylline in plasma
Marwa F. B. Ali, Ibrahim A. Darwısh, Noha M. Hosny
Microchemical Journal (2025), pp. 112911-112911
Closed Access | Times Cited: 2
Advancing macromolecular structure determination with microsecond X-ray pulses at a 4th generation synchrotron
Julien Orlans, Samuel L. Rose, Gavin Ferguson, et al.
Communications Chemistry (2025) Vol. 8, Iss. 1
Open Access | Times Cited: 1
Cyclic nucleotide phosphodiesterases as drug targets
Michy P. Kelly, Viacheslav O. Nikolaev, Leila Gobejishvili, et al.
Pharmacological Reviews (2025) Vol. 77, Iss. 3, pp. 100042-100042
Open Access | Times Cited: 1
Cognitive Impairment in Parkinson’s Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches
Yıldız Değirmenci, Efthalia Angelopoulou, Vasiliki Georgakopoulou, et al.
Medicina (2023) Vol. 59, Iss. 10, pp. 1756-1756
Open Access | Times Cited: 16
Comparative Safety of Istradefylline Among Parkinson Disease Adjunctive Therapies: A Systematic Review and Meta-analysis of Randomized Controlled Studies
Yasar Torres‐Yaghi, Joyce Qian, Hannah Cummings, et al.
Clinical Neuropharmacology (2025) Vol. 48, Iss. 1, pp. 7-12
Closed Access
A Bright Future for Photopharmaceuticals Addressing Central Nervous System Disorders: State of the Art and Challenges Toward Clinical Translation
Rudolf L. Z. Ganzoni, Sofie S. Bournons, Erick M. Carreira, et al.
Medicinal Research Reviews (2025)
Closed Access
Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression
Peter Riederer, Sabrina Strobel, Toshiharu Nagatsu, et al.
Journal of Neural Transmission (2025)
Open Access
Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs
Nbaa Masood, Joohi Jimenez‐Shahed
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 247-266
Open Access | Times Cited: 9
Molecular docking/dynamics simulations, MEP analysis, bioisosteric replacement and ADME/T prediction for identification of dual targets inhibitors of Parkinson’s disease with novel scaffold
Merzaka Mettai, Ismail Daoud, Fouzia Mesli, et al.
In Silico Pharmacology (2023) Vol. 11, Iss. 1
Closed Access | Times Cited: 8
Adenosine receptor signalling as a driver of pulmonary fibrosis
Emily Cash, Amanda Goodwin, Amanda L. Tatler
Pharmacology & Therapeutics (2023) Vol. 249, pp. 108504-108504
Open Access | Times Cited: 8
Drug repurposing for neurodegenerative diseases
Halak Shukla, D. James B. St. John, Shuvomoy Banerjee, et al.
Progress in molecular biology and translational science (2024), pp. 249-319
Closed Access | Times Cited: 2
Exploring Oxidative Stress in Disease and Its Connection with Adenosine
Ana Salomé Correia, Nuno Vale
Oxygen (2024) Vol. 4, Iss. 3, pp. 325-337
Open Access | Times Cited: 2
Cognitive Impairment in Parkinson’s Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches
Yıldız Değirmenci, Efthalia Angelopoulou, Vasiliki Georgakopoulou, et al.
(2023)
Open Access | Times Cited: 6
Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?
Silvia Rota, Daniele Urso, Daniel J. van Wamelen, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 9
Computational exploration of acefylline derivatives as MAO-B inhibitors for Parkinson’s disease: insights from molecular docking, DFT, ADMET, and molecular dynamics approaches
Ali Irfan, Ameer Fawad Zahoor, Yassir Boulaamane, et al.
Frontiers in Chemistry (2024) Vol. 12
Open Access | Times Cited: 1
Caffeine alleviates anxiety-like behavior and brainstem lesions in a rotenone-induced rat model of Parkinson's disease
Timileyin Adewumi Adeyeye, Bamidele Richard Babatunde, Samuel Ehimare Ehireme, et al.
Journal of Chemical Neuroanatomy (2023) Vol. 132, pp. 102315-102315
Closed Access | Times Cited: 3
Most Potential Neuroprotective compound isolated from Allium sativum Targeting Alpha Synuclein involved in Parkinson’s Disease identified through Molecular Docking and MTT Assay
S Rehan Ahmad, Md. Zeyaullah, Abdullah M. AlShahrani, et al.
Research Square (Research Square) (2024)
Closed Access
Prolonged intermittent theta burst stimulation restores the balance between A2AR- and A1R-mediated adenosine signaling in the 6-hydroxidopamine model of Parkinson’s disease
Milica Zeljković, Jelena Stanojević, Ivana Stevanović, et al.
Neural Regeneration Research (2024) Vol. 20, Iss. 7, pp. 2053-2067
Open Access
Drosophila PD model
Fatma E. Sayed, Aya Khaled Mahmoud, Omaima Ali Mostafa Mohammed, et al.
Elsevier eBooks (2024), pp. 231-245
Closed Access
Pharmacophore modelling and molecular dynamics simulation to identify novel molecules targeting catechol-O-methyltransferase and dopamine D3 receptor to combat Parkinson’s disease
Amitha Joy, Sidharth Menon, Neethu Mariam Thomas, et al.
Polymer Bulletin (2023) Vol. 81, Iss. 9, pp. 7893-7917
Closed Access | Times Cited: 1
Page 1

Scroll to top